Featured Research

from universities, journals, and other organizations

Muscular Dystrophy: New Drug Promises Benefit Without Risk Of Infection

Date:
June 19, 2009
Source:
Wiley-Blackwell
Summary:
A new drug being studied for the treatment of muscle degenerating diseases has shown promising results. According to a study, Debio 025 is as effective as current drugs but, crucially, does not cause unwanted immunosuppressive effects.

A new drug being studied for the treatment of muscle degenerating diseases has shown promising results. According to a study published today in the British Journal of Pharmacology, Debio 025 is as effective as current drugs but, crucially, does not cause unwanted immunosuppressive effects.

Bethlem Myopathy and Ullrich Congenital Muscular Dystrophy (UCMD) are muscle wasting diseases caused by deficiencies in collagen VI, a component of connective tissue. Patients are usually diagnosed at birth and suffer from muscle weakness that worsens over time. UCMD patients often also suffer respiratory failure, which is complicated by lung infections. Although the drug cyclosporin A (CsA) offers some benefit for these patients, its long term use may be undesirable because it interacts with calcineurin, an important immunoregulatory protein.

"Long-term treatment with CsA is risky because it suppresses the immune system, making patients more susceptible to life-threatening lung infections," says Paolo Bernardi, who led the team at the University of Padova in Italy. "Our findings suggest Debio 025 may provide a safer alternative".

In the study, mice suffering from a muscle-wasting disease similar to human muscular dystrophy were protected when treated with Debio 025. The researchers studied muscle cells from mice given the drug for five days and found decreases in numbers of abnormal muscle fibres similar to those reported in studies of treatment with CsA. They were also able to show that Debio 025, although related to CsA, was not targeting calcineurin.

"This drug has no effects on the immune system and therefore could be used for prolonged periods of time without increasing risk of infection. We should be able to treat children affected by these forms of muscular dystrophy and possibly slow down or even stop the progression of the disease," says Bernardi.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Cite This Page:

Wiley-Blackwell. "Muscular Dystrophy: New Drug Promises Benefit Without Risk Of Infection." ScienceDaily. ScienceDaily, 19 June 2009. <www.sciencedaily.com/releases/2009/06/090610192437.htm>.
Wiley-Blackwell. (2009, June 19). Muscular Dystrophy: New Drug Promises Benefit Without Risk Of Infection. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2009/06/090610192437.htm
Wiley-Blackwell. "Muscular Dystrophy: New Drug Promises Benefit Without Risk Of Infection." ScienceDaily. www.sciencedaily.com/releases/2009/06/090610192437.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins